BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL;  Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5:776-787. [PMID: 32585136 DOI: 10.1016/s2468-1253(20)30190-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Brizawasi A, Ahirwar AK, Prabhat, Kaim K, Ahirwar P, Kumawat R, Prasad J. COVID-19: a viewpoint from hepatic perspective. Horm Mol Biol Clin Investig 2022. [PMID: 36190156 DOI: 10.1515/hmbci-2022-0026] [Reference Citation Analysis]
2 Ding C, Hong Y, Che Y, He T, Wang Y, Zhang S, Wu J, Xu W, Hou J, Hao H, Cao L. Bile acid restrained T cell activation explains cholestasis aggravated hepatitis B virus infection. FASEB J 2022;36:e22468. [PMID: 35913801 DOI: 10.1096/fj.202200332R] [Reference Citation Analysis]
3 Li P, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother 2022;154:113568. [PMID: 36029543 DOI: 10.1016/j.biopha.2022.113568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen H, Chen Q. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD. Int J Biol Sci 2022;18:4756-67. [PMID: 35874945 DOI: 10.7150/ijbs.72461] [Reference Citation Analysis]
5 Jiang SX, Schwab K, Enns R, Ko HH. Survey of the Impact of COVID-19 on Chronic Liver Disease Patient Care Experiences and Outcomes. Journal of the Canadian Association of Gastroenterology 2022. [DOI: 10.1093/jcag/gwac022] [Reference Citation Analysis]
6 Restrepo-gutiérrez JC, Toro-montoya AI. Enfermedad hepatobiliar asociada a COVID-19. Hepatología 2022. [DOI: 10.52784/27112330.155] [Reference Citation Analysis]
7 Pichugina IM, Ogoltsova IM. Jaundice as an atypical manifestation of the new coronavirus infection. Case report. Consilium Medicum 2022;24:343-348. [DOI: 10.26442/20751753.2022.5.201538] [Reference Citation Analysis]
8 Makiyah A, Aa Juhanda. Pendampingan Kebiasaan Protokol Kesehatan di Era New Normal Covid-19 Lingkungan Keluarga Bagi Perawat. J Inov Penelit dan Pengabdi Masy 2022;2:86-100. [DOI: 10.53621/jippmas.v2i1.121] [Reference Citation Analysis]
9 Saleem F, Alnasrallah W, Malik MI, Rehman SU. Factors Affecting the Quality of Online Learning During COVID-19: Evidence From a Developing Economy. Front Educ 2022;7:847571. [DOI: 10.3389/feduc.2022.847571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Davies A, Åsenius F, Purcell F, Wu M, Al-rubaye A, Alrubaiy L. THE PATTERN AND LONG TERM FOLLOW UP OF COVID-19 RELATED ABNORMAL LIVER BLOOD TESTS. ijsr. [DOI: 10.36106/ijsr/6020892] [Reference Citation Analysis]
11 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Klara F, Ristiono R. Identifikasi Faktor Penyebab Kesulitan Belajar Siswa yang Pembelajarannya dalam Jaringan (Daring) Kelas XI. JLLS 2021;4:350-356. [DOI: 10.23887/jlls.v4i3.38819] [Reference Citation Analysis]
13 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sweed D, Abdelsameea E, Khalifa EA, Abdallah H, Moaz H, Moaz I, Abdelsattar S, Abdel-Rahman N, Mosbeh A, Elmahdy HA, Sweed E. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liver J 2021;11:64. [PMID: 34777871 DOI: 10.1186/s43066-021-00123-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, Wong GL. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open 2021;11:e052310. [PMID: 34670765 DOI: 10.1136/bmjopen-2021-052310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Trukhan DI, Davydov EL. Liver drug damage: possibilities of polyionic succinate-methioninic complex during the pandemic of new coronavirus infection (COVID-19). Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-110-121] [Reference Citation Analysis]
17 Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, Farsi Y, Nasiri MJ. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne) 2021;8:731436. [PMID: 34616757 DOI: 10.3389/fmed.2021.731436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
18 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology 2021;74:1750-65. [PMID: 33961298 DOI: 10.1002/hep.31890] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
20 Gandhi M, Ling WH, Chen CH, Lee JH, Kudo M, Chanwat R, Strasser SI, Xu Z, Lai SH, Chow PK. Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. J Hepatocell Carcinoma 2021;8:1159-67. [PMID: 34589445 DOI: 10.2147/JHC.S329018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
21 Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? World J Gastroenterol 2021; 27(36): 6039-6052 [PMID: 34629818 DOI: 10.3748/wjg.v27.i36.6039] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Samidoust P, Esmaeili Delshad MS, Navid Talemi R, Mojtahedi K, Samidoust A, Jahangiri S, Ashoobi MT. Incidence, characteristics, and outcome of COVID-19 in patients on liver transplant program: a retrospective study in the north of Iran. New Microbes New Infect 2021;44:100935. [PMID: 34493955 DOI: 10.1016/j.nmni.2021.100935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
24 Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol 2021;34:625-33. [PMID: 34475732 DOI: 10.20524/aog.2021.0628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Testino G, Vignoli T, Patussi V, Allosio P, Amendola MF, Aricò S, Baselice A, Balbinot P, Campanile V, Fanucchi T, Greco G, Macciò L, Meneguzzi C, Mioni D, Palmieri VO, Parisi M, Renzetti D, Rossin R, Gandin C, Bottaro LC, Bernardi M, Addolorato G, Lungaro L, Zoli G, Scafato E, Caputo F. Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). Dig Dis Sci 2021. [PMID: 34142284 DOI: 10.1007/s10620-021-07006-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Murthy P, Narasimha VL. Effects of the COVID-19 pandemic and lockdown on alcohol use disorders and complications. Curr Opin Psychiatry 2021;34:376-85. [PMID: 34016817 DOI: 10.1097/YCO.0000000000000720] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
27 Yen HH, Su PY, Liu II, Zeng YH, Huang SP, Hsu YC, Hsu PK, Chen YY. Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study. BMC Gastroenterol 2021;21:209. [PMID: 33964873 DOI: 10.1186/s12876-021-01792-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
28 Su HY, Hsu YC. Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives . World J Clin Cases 2021; 9(13): 2951-2968 [PMID: 33969082 DOI: 10.12998/wjcc.v9.i13.2951] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Satsangi S, Gupta N, Kodan P. Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. J Clin Transl Hepatol 2021;9:436-46. [PMID: 34221930 DOI: 10.14218/JCTH.2020.00174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Singh A, Premkumar M, Singh V. Liver injury in COVID-19 - The culprit may not be COVID-19! J Hepatol 2021;75:739-40. [PMID: 33753154 DOI: 10.1016/j.jhep.2021.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 M'bodj K, Abid H, Adil N, Abkari ME, Aqodad N. What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review. Pan Afr Med J 2021;38:225. [PMID: 34046130 DOI: 10.11604/pamj.2021.38.225.28123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sahu T, Mehta A, Ratre YK, Jaiswal A, Vishvakarma NK, Bhaskar LVKS, Verma HK. Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings. World J Gastroenterol 2021; 27(6): 449-469 [PMID: 33642821 DOI: 10.3748/wjg.v27.i6.449] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
34 Mao R, Rieder F, Ben-Horin S, Kaplan GG, Ng SC, Wong GL, Ghosh S, Chen MH. Implications of COVID-19 for patients with pre-existing digestive diseases: an update. Lancet Gastroenterol Hepatol. 2021;6:258-260. [PMID: 33539813 DOI: 10.1016/s2468-1253(21)00025-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Han MW, Wang M, Xu MY, Qi WP, Wang P, Xi D. Clinical features and potential mechanism of coronavirus disease 2019-associated liver injury. World J Clin Cases 2021; 9(3): 528-539 [PMID: 33553391 DOI: 10.12998/wjcc.v9.i3.528] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 An YW, Song S, Li WX, Chen YX, Hu XP, Zhao J, Li ZW, Jiang GY, Wang C, Wang JC, Yuan B, Liu HQ. Liver function recovery of COVID-19 patients after discharge, a follow-up study. Int J Med Sci. 2021;18:176-186. [PMID: 33390786 DOI: 10.7150/ijms.50691] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 23.0] [Reference Citation Analysis]
37 Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther 2021;38:423-40. [PMID: 33145648 DOI: 10.1007/s12325-020-01535-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
38 Thompson S, Bohn M, Mancini N, Loh T, Wang C, Grimmler M, Yuen K, Mueller R, Koch D, Sethi, S, Rawlinson W, Clementi, M, Erasmus R, Leportier M, Kwon G, Menezes M, Patru M, Gramegna M, Singh K, Najjar O, Ferrari, M, Lippi G, Adeli, K, Horvath A. IFCC Interim Guidelines on Biochemical/ Hematological Monitoring of COVID-19 Patients. Lab sluzh 2021;10:55. [DOI: 10.17116/labs20211004155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhang D, Zhu Z, Bi J, Feng D, Zhang L, Liu H, Gao Y. Clinical Characteristics and Risk Factors in Coronavirus Disease 2019 Patients with Liver Injury. Med Sci Monit 2020;26:e928849. [PMID: 33339813 DOI: 10.12659/MSM.928849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Huang CF, Wu PF, Yeh ML, Huang CI, Liang PC, Hsu CT, Hsu PY, Liu HY, Huang YC, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clin Mol Hepatol 2021;27:136-43. [PMID: 33317253 DOI: 10.3350/cmh.2020.0150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
41 Sy-Janairo ML, Y Cua IH. Association of metabolic-associated fatty liver disease and risk of severe coronavirus disease 2019 illness.JGH Open. 2020;. [PMID: 33363258 DOI: 10.1002/jgh3.12465] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
42 Bang CS. Clinical Implication of Gastrointestinal and Liver Manifestations in the COVID-19 Pandemic Era. Korean J Gastroenterol 2020;76:268-271. [DOI: 10.4166/kjg.2020.137] [Reference Citation Analysis]
43 Yang M, Lai CL. SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? Cell Death Discov 2020;6:130. [PMID: 33251029 DOI: 10.1038/s41420-020-00369-w] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
44 Jeon D, Son M, Choi J. Impact of Liver Cirrhosis on the Clinical Outcomes of Patients with COVID-19: A Nationwide Cohort Study of Korea. Korean J Intern Med. [DOI: 10.3904/kjim.2020.486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Lui RN. Safety in endoscopy for patients and healthcare workers during the COVID-19 pandemic. Tech Innov Gastrointest Endosc. 2020;. [PMID: 33103130 DOI: 10.1016/j.tige.2020.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Wiśniewska H, Skowron M, Bander D, Hornung M, Jurczyk K, Karpińska E, Laurans Ł, Socha Ł, Czajkowski Z, Wawrzynowicz-Syczewska M. Nosocomial COVID-19 Infection and Severe COVID-19 Pneumonia in Patients Hospitalized for Alcoholic Liver Disease: A Case Report. Am J Case Rep 2020;21:e927452. [PMID: 32973125 DOI: 10.12659/AJCR.927452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kakakhel MA, Wu F, Khan TA, Feng H, Hassan Z, Anwar Z, Faisal S, Ali I, Wang W. The first two months epidimiological study of COVID-19, related public health preparedness, and response to the ongoing epidemic in Pakistan. New Microbes New Infect 2020;37:100734. [PMID: 32884821 DOI: 10.1016/j.nmni.2020.100734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]